DrugPatentWatch Database Preview
Exela Pharma Scs Llc Company Profile
What is the competitive landscape for EXELA PHARMA SCS LLC, and when can generic versions of EXELA PHARMA SCS LLC drugs launch?
EXELA PHARMA SCS LLC has eight approved drugs.
There is one US patent protecting EXELA PHARMA SCS LLC drugs.
Drugs and US Patents for Exela Pharma Scs Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exela Pharma Scs Llc | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 018925-002 | Apr 5, 2018 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
Exela Pharma Scs Llc | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 018925-001 | Mar 30, 1984 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
Exela Pharma Scs Llc | NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | sodium nitroprusside | SOLUTION;INTRAVENOUS | 209387-001 | Mar 8, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
Exela Pharma Scs Llc | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-001 | Jul 11, 2018 | RX | No | No | ➤ Sign Up | ➤ Sign Up | |||||
Exela Pharma Scs Llc | POTASSIUM ACETATE | potassium acetate | INJECTABLE;INJECTION | 206203-001 | Dec 29, 2015 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
Exela Pharma Scs Llc | NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | sodium nitroprusside | SOLUTION;INTRAVENOUS | 209387-002 | Dec 7, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
Exela Pharma Scs Llc | MAGNESIUM SULFATE | magnesium sulfate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 206039-001 | Dec 18, 2014 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.